View Item 

Show simple item record

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials

dc.contributor.authorSchoenfeld, P.en_US
dc.contributor.authorPimentel, M.en_US
dc.contributor.authorChang, L.en_US
dc.contributor.authorLembo, A.en_US
dc.contributor.authorChey, W. D.en_US
dc.contributor.authorYu, J.en_US
dc.contributor.authorPaterson, C.en_US
dc.contributor.authorBortey, E.en_US
dc.contributor.authorForbes, W. P.en_US
dc.date.accessioned2014-05-23T15:59:01Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-23T15:59:01Z
dc.date.issued2014-05en_US
dc.identifier.citationSchoenfeld, P.; Pimentel, M.; Chang, L.; Lembo, A.; Chey, W. D.; Yu, J.; Paterson, C.; Bortey, E.; Forbes, W. P. (2014). "Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials." Alimentary Pharmacology & Therapeutics 39(10): 1161-1168.en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106831
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherSalix Pharmaceuticals, Inc.en_US
dc.titleSafety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trialsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106831/1/apt12735.pdf
dc.identifier.doi10.1111/apt.12735en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceGarey KW, Ghantoji SS, Shah DN, et al. A randomized, double‐blind, placebo‐controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66: 2850 – 5.en_US
dc.identifier.citedreferencePimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22 – 32.en_US
dc.identifier.citedreferenceLembo A, Zakko SF, Ferreira NL, et al. Rifaximin for the treatment of diarrhea‐associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008; 134: A – 545.en_US
dc.identifier.citedreferenceClinicalTrials.gov. Study to assess the efficacy and safety of rifaximin administered BID in the treatment of patients with diarrhea‐associated irritable bowel syndrome. Clinicaltrials.gov. December 21, 2009. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00269412?term=rifaximin+IBS&rank=9. Accessed January 15, 2013.en_US
dc.identifier.citedreferenceMeyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36: 1084 – 93.en_US
dc.identifier.citedreferencePeralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome‐related symptoms: experience with rifaximin. World J Gastroenterol 2009; 15: 2628 – 31.en_US
dc.identifier.citedreferenceEsposito I, de Leon A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non‐absorbable antibiotics. World J Gastroenterol 2007; 13: 6016 – 21.en_US
dc.identifier.citedreferenceMajewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139 – 42.en_US
dc.identifier.citedreferenceLessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012; 55 ( Suppl. 2 ): S65 – 70.en_US
dc.identifier.citedreferencePrantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Rifaximin‐extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473 – 81.en_US
dc.identifier.citedreferenceBass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071 – 81.en_US
dc.identifier.citedreferenceGastrointestinal Drugs Advisory Committee. XIFAXAN ® (Rifaximin) Tablets, 550 Mg, NDA 21‐361: Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting, 16 November 2011. Silver Springs, MD: U.S. Department of Health & Human Services; U.S. Food and Drug Administration, 2011. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/gastrointestinaldrugsadvisorycommittee/ucm279646.pdf. Accessed January 14, 2013.en_US
dc.identifier.citedreferenceSanyal A, Mullen KD, Bass NM, et al. Rates of commonly occurring infections in cirrhosis patients remain stable during long‐term rifaximin treatment. J Hepatol 2012; 56: S255 – 6.en_US
dc.identifier.citedreferenceShah D, Dang MD, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010; 8: 555 – 64.en_US
dc.identifier.citedreferenceVenugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012; 55: S71 – 6.en_US
dc.identifier.citedreferenceMattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2013; 37: 122 – 8.en_US
dc.identifier.citedreferenceRubin DT, Sohi S, Glathar M, Thomas T, Yadron N, Surma BL. Rifaximin is effective for the treatment of Clostridium difficile ‐associated diarrhea: results of an open‐label pilot study. Gastroenterol Res Pract 2011; 2011: 106978.en_US
dc.identifier.citedreferenceBasu PP, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole‐unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol 2010; 3: 221 – 5.en_US
dc.identifier.citedreferenceScarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 ( Suppl. 1 ): 36 – 66.en_US
dc.identifier.citedreferenceDe Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979 – 81.en_US
dc.identifier.citedreferenceDuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram‐negative flora and enterococci. Clin Microbiol Infect 2004; 10: 1009 – 11.en_US
dc.identifier.citedreferenceKothary V, Scherl EJ, Bosworth B, et al. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of PAbN‐inhibitable efflux pumps. Antimicrob Agents Chemother 2013; 57: 811 – 7.en_US
dc.identifier.citedreferenceCarman RJ, Boone JH, Grover H, Wickham KN, Chen L. In vivo selection of rifamycin‐resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother 2012; 56: 6019 – 20.en_US
dc.identifier.citedreferenceBrandt LJ, Chey WD, Foxx‐Orenstein AE, et al. An evidence‐based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 ( Suppl. 1 ): S1 – 35.en_US
dc.identifier.citedreferenceLongstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480 – 91.en_US
dc.identifier.citedreferenceShah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012; 125: 381 – 93.en_US
dc.identifier.citedreferenceTack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011; 364: 81 – 2.en_US
dc.identifier.citedreferenceMenees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta‐analysis. Am J Gastroenterol 2012; 107: 28 – 35.en_US
dc.identifier.citedreferenceAdachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42: 541 – 7.en_US
dc.identifier.citedreferenceBasseri RJ, Weitsman S, Barlow GM, Pimentel M. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY) 2011; 7: 455 – 93.en_US
dc.identifier.citedreferenceXifaxan (rifaximin) tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc., 2012.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12735.pdf
Size:
130.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.